Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace, Inc. reports company developments as a medical device company focused on epilepsy care through the RNS System, a brain-responsive neuromodulation platform that monitors brain electrical activity and delivers personalized electrical stimulation at the seizure source. Recurring updates cover RNS System revenue, financial results, gross margin, research and development spending, and corporate outlook commentary.
NeuroPace news also includes clinical evidence for drug-resistant focal epilepsy and broader epilepsy programs, including post-approval study publications and NAUTILUS trial presentations. Additional announcements include healthcare conference presentations, investor communications, product-platform development, AI-enabled tools, and other clinical or regulatory disclosures tied to responsive neurostimulation.
NeuroPace (Nasdaq: NPCE) will present at the Leerink 2026 Global Healthcare Conference on March 11, 2026 at 8:40am PT in Miami, FL. Management will also host investor meetings during the conference.
The presentation will be available via live webcast and a replay will be posted for thirty days in the Events & Presentations section of NeuroPace’s investor website.
NeuroPace (Nasdaq: NPCE) reported Q4 2025 revenue of $26.6M (+24% YoY) and full-year 2025 revenue of $100.0M (+25% YoY). RNS System revenue was $22.4M in Q4 and $81.7M for 2025. Gross margin improved to 77.4% in Q4 and 77.2% for the year.
The company submitted a PMA supplement for IGE, expects potential mid-2026 approval, received higher Medicare reimbursement rates for implants/replacements, and reiterated 2026 guidance with 20–22% core RNS growth and revenue guidance of $98–$100M.
NeuroPace (Nasdaq: NPCE) will report fourth-quarter 2025 financial results after market close on March 3, 2026. Management will host a webcast and conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Investors can join via a live webcast or by telephone at +1 (800) 715-9871 (Conference ID 8467256). The webcast will be archived on the company investor relations events page and available for replay for at least 90 days.
NeuroPace (Nasdaq: NPCE) reported preliminary unaudited results for Q4 and FY2025 and gave initial 2026 outlook. FY2025 revenue ~ $100.0M (+25% vs 2024) and Q4 2025 revenue ~ $26.6M (+24% vs Q4 2024). RNS revenue was ~ $81.7M for FY2025 (+25%) and ~ $22.4M for Q4 (+26%). Cash and short-term investments were $61.1M at 12/31/2025. The company expects 2026 revenue $98M–$100M, assuming 20%–22% growth in core RNS revenue and no contribution from IGE, Service revenue, or DIXI. Gross margin is expected at 81%–82% for 2026 versus preliminary 77.2% in 2025. A PMA supplement for an IGE indication was filed; potential approval could follow in the second half of 2026.
NeuroPace (Nasdaq: NPCE) said its management team will present at the 44th Annual J.P. Morgan Healthcare Conference at 3:00 PM PT on Wednesday, January 14, 2026 in San Francisco.
Management will host investor meetings during the conference. The presentation will be available via live webcast, with a replay accessible for 30 days in the Events & Presentations section of NeuroPace’s investor website.
NeuroPace (Nasdaq: NPCE) filed a PMA supplement with the U.S. Food and Drug Administration on December 17, 2025, seeking to expand the RNS System indication to antiseizure‑medication (ASM) resistant idiopathic generalized epilepsy (IGE) with generalized tonic‑clonic (GTC) seizures.
The submission is supported by preliminary 18‑month NAUTILUS data showing a 77% median GTC seizure reduction and a favorable safety profile, and the RNS System has received Breakthrough Device Designation for this IGE indication. Under current FDA guidance, PMA supplements are typically reviewed in about 180 days, although actual review times may vary.
NeuroPace (Nasdaq: NPCE) reported preliminary 18-month results from the ongoing NAUTILUS1 trial of the RNS System in drug-resistant idiopathic generalized epilepsy (IGE) with generalized tonic-clonic (GTC) seizures.
Key results: a 77% median reduction in GTC seizures versus baseline at 18 months (p<0.001), rapid and sustained reductions in GTCs and seizure-free days, Clinical Global Impression of Change >80% among patients and physicians, and safety consistent with the established RNS System profile (p<0.0001). NeuroPace said it remains on track to submit a PMA supplement to the FDA to expand the RNS indication to IGE by year-end 2025.
NeuroPace (Nasdaq: NPCE) will spotlight clinical outcomes and AI tools for epilepsy at the 2025 American Epilepsy Society Annual Meeting in Atlanta (Dec 6–7, 2025).
Highlights include 18-month NAUTILUS safety and efficacy results for idiopathic generalized epilepsy, new Post-Approval Study analyses showing seizure reduction durability at three years+, demonstrations of next-generation NeuroPace AI and SeizureID, and the RNS System featured across 80+ scientific presentations and posters.
NeuroPace will host a Product Theater on Dec 7, 2025 2:30–3:30 PM and will be at Booth #125 for demos and tech suite sessions.
NeuroPace (NASDAQ: NPCE) announced Medicare reimbursement increases for the RNS System under the CY 2026 Physician Fee Schedule (PFS) and Outpatient Prospective Payment System (OPPS) final rules.
Key changes: PFS raises professional payments ~43% (+$530) for initial implant and ~45% (+$260) for replacements; OPPS reassigns RNS replacement CPT 61891 to the highest-paying neurostimulator APC, boosting average hospital Medicare reimbursement by 47% from $21,444 (CY 2025) to $31,526 effective January 1, 2026.
Company commentary notes these updates could better reflect provider resources, support neurosurgeon adoption and procedure growth, and provide a tailwind as replacement procedures grow as a business contributor.
NeuroPace (NASDAQ: NPCE) reported Q3 2025 revenue of $27.4M, up 30% year‑over‑year, with RNS System revenue of $22.6M (+31%). Gross margin was 77.4%. Net loss was $3.5M and loss from operations was $2.6M. Cash, cash equivalents and short‑term investments were $60.0M and long‑term borrowings were $58.7M as of Sept 30, 2025.
The company increased full‑year 2025 revenue guidance to $97M–$98M (growth 21%–23%) and raised gross margin guidance to 76%–77%. Operational updates include submitting Seizure ID to the FDA, a completed FDA pre‑submission for the NAUTILUS IGE study, and plans to submit a PMA supplement for IGE by year‑end 2025.